Furthermore, another group showed that targeting collagen stabilization (crosslinking) using a LOX inhibitor in combination with anti-PD-1 in vivo, not only reduced overall tumor stiffness but also allowed for improved T-cell migration in the melanoma TME, thereby improving the overall efficacy of this immunotherapy (138). Here, PDCD1 is linked to melanoma.